原发灶不明转移癌基因表达谱分析技术进展

doi:10.11904/j.issn.1002-3070.2017.06.014

摘要/Abstract

摘要： 原发灶不明转移癌(CUP)是一类经组织病理学证实为转移性,但经多种临床诊疗手段无法明确原发灶的肿瘤。明确肿瘤原发部位是CUP诊断的第一步,组织病理学、免疫组织化学技术、PET/CT都是临床常用的诊疗手段。基因表达谱分析技术是近年新兴的一种诊断原发灶的方法,具有较高的诊断准确率、敏感性和特异性,有望实现CUP患者的个体化治疗。

关键词: 原发灶不明转移癌, 基因表达谱分析技术, 诊断进展

Abstract: Primary lesions unknown metastatic cancer (CUP)is a class of histopathologically confirmed metastases.However,a variety of clinical diagnosis and treatment can not clear the primary tumor.The identification of tumor primary site is the first step in the diagnosis of CUP.The histopathology,immunohistochemistry and PET /CT are commonly used clinical diagnosis and treatment.Gene expression profiling technique is a new method for the diagnosis of primary tumor in recent years.It has high diagnostic accuracy,sensitivity and specificity,and is expected to achieve individual treatment of patients with CUP.

Key words: Cancer of unknown primary sites(CUP), Gene expression profiling(GEP), Progress in diagnosis

中图分类号:

韩倩, 林连君, 刘新民校审. 原发灶不明转移癌基因表达谱分析技术进展[J]. 实用肿瘤学杂志, 2017, 31(6): 554-558.

HAN Qian, LIN Lianjun, LIU Xinmin. Advances in gene expression profiling of metastases from unidentified primary tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 554-558.

参考文献

1 National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology.Occult primary(cancer of unknown primary[CUP]),version 2.2016[M/OL].https://www.nccn.org/professionals/physician_gls/f_guidelines.asp,2016.
2 Greco FA.Cancer of unknown primary site:still an entity,a biological mystery and a metastatic model[J].Nat Rev Cancer,2014,14(1):3-4.
3 Hainsworth JD,Greco FA.Gene expression profiling in patients with carcinoma of unknown primary site:from translational research to standard of care[J].Virchows Arch,2014,464(4):393-402.
4 Wang G,Wu Y,Zhang W,et al.Clinical value of whole-body ¹⁸F fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary[J].J Med Imaging Radiat Oncol,2013,57(1):65-71.
5 Riaz S,Nawaz MK,Faruqui ZS,et al.Diagnostic accuracy of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary[J].Mol Imaging Radionucl Ther,2016,25(1):11-18.
6 Hemminki K,Liu H,Heminki A,et al.Power and limits of modern cancer diagnostics:cancer of unknown primary[J].Ann Oncol,2012,23(3):760-764.
7 Burglin SA,Hess S,Hoilund-carlsen PF,et al.¹⁸F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary:A systematic review and meta-analysis[J].Medicine,2017,96(16):e6713.
8 Varadhachary GR,Raber MN.Cancer of unknown primary site[J].N Engl J Med,2014,371(8):757-765.
9 Pentheroudakis G,Spector Y,Krikelis D,et al.Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary(CUP)demonstrates no significant expression differences with metastases of matched known primary tumors[J].Clin Exp Metastasis,2013,30(4):431-439.
10 Ma XJ,Patel R,Wang X,et al.Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay[J].Arch Pathol Lab Med,2006,130(4):465-473.
11 Tothill RW,Shi F,Paiman L,et al.Development and validation of a gene expression tumour classifier for cancer of unknown primary[J].Pathology,2015,47(1):7-12.
12 Brachtel EF,Operana TN,Suillivan PS,et al.Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples[J].Oncotarget,2016,7(19):27220-27231.
13 Monzon FA,Lyons-weiler M,Buturovic LJ,et al.Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin[J].J Clin Oncol,2009,27(15):2503-2508.
14 Horlings HM,Vanlaar RK,Kerst JM,et al.Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary[J].J Clin Oncol,2008,26(27):4435-4441.
15 Rosenfeld N,Aharonov R,Meiri E,et al.MicroRNAs accurately identify cancer tissue origin[J].Nat Biotechnol,2008,26(4):462-469.
16 Solilde R,Vincent M,Moller AK,et al.Efficient identification of miRNAs for classification of tumor origin[J].J Mol Diagn,2014,16(1):106-115.
17 Ferracin M,Pedriali M,Veronese A,et al.MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin[J].J Pathol,2011,225(1):43-53.
18 Meiri E,Mueller WC,Rosenwald S,et al.A second-generation microRNA-based assay for diagnosing tumor tissue origin[J].The Oncologist,2012,17(6):801-8012.
19 Pentheroueakis G,Pavlidis N,Fountzilas G,et al.Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary[J].Mol Cancer,2013,12(57):1-8.
20 Moran S,Arribas C,Esteller M.Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences[J].Epigenomics,2016,8(3):389-399.
21 Elizabeth M,Matthew LZ,Yang ZH,et al.A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells[J].Oncotarget,2015,7(4):15.
22 Economopoulou P,Mountzios G,Pavlidis N,et al.Cancer of unknown primary origin in the genomic era: Elucidating the dark box of cancer[J].Cancer Treat Rev,2015,41(7):598-604.
23 Handorf CR,Kulkarni A,Grenert JP,et al.A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors[J].Am J Surg Pathol,2013,37(7):1067-1075.
24 Greco FA,Lennington WJ,Spigel DR,et al.Poorly differentiated neoplasms of unknown primary site:diagnostic usefulness of a molecular cancer classifier assay[J].Mol Diagn Ther,2015,19(2):91-97.
25 Weiss LM,Chu P,Schroeder BE,et al.Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors[J].J Mol Diagn,2013,15(2):263-269.
26 Greco FA,Lennington WJ,Spigel DR,et al.Molecular profiling diagnosis in unknown primary cancer:accuracy and ability to complement standard pathology[J].J Natl Cancer Inst,2013,105(11):782-790.
27 Kerr SE,Schnabel CA,Sullivan PS,et al.A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors[J].Mod Pathol,2014,27(1):44-54.
28 Kerr SE,Schabel CA,Sullivan PS,et al.Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier[J].Clin Cancer Res,2012,18(14):3952-3960.
29 Loffler H,Pfarr N,Kriegsmann M,et al.Molecular driver alterations and their clinical relevance in cancer of unknown primary site[J].Oncotarget,2016,7(28):44322-44329.
30 Ross JS,Wang K,Gay L,et al.Comprehensive genomic profiling of carcinoma of unknown primary site:new routes to targeted therapies[J].JAMA Oncol,2015,1(1):40-49.
31 Gatalica Z,Millis SZ,Vranic S,et al.Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site:Analysis of 1806 cases[J].Oncotarget,2014,5(23):12440-12447.
32 Ali SM,Sanford EM,Klempner SJ,et al.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies[J].Oncologist,2015,20(5):499-507.
33 Varadhachary G.Carcinoma of unknown primary site:the poster child for personalized medicine? [J].JAMA Oncol,2015,1(1):19-21.
34 Kamposioras K,Pentheroudakis G,Pavlidis N.Exploring the biology of cancer of unknown primary:breakthroughs and drawbacks[J].Eur J Clin Invest,2013,43(5):491-500.
35 Nystrom SJ,Hornberger JC,Varadhachary GR,et al.Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer:impact on diagnosis,treatment,and survival[J].Oncotarget,2012,3(6):620-628.
36 Hainsworth JD,Schnabel CA,Erlander MG,et al.A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile[J].Clin Colorectal Cancer,2012,11(2):112-118.
37 Hainsworth JD,Rubin MS,Spigel DR,et al.Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site:a prospective trial of the Sarah Cannon research institute[J].J Clin Oncol,2013,31(2):217-223.
38 Gross-goupil M,Massard C,Lesimple T,et al.Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary(CUP):a feasibility study from the GEFCAPI[J].Oncologie,2012,35(1/2):54-55.
39 Le Tourneau C,Delord JP,Goncalves A,et al.Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer(SHIVA):a multicentre,open-label,proof-of-concept,randomised,controlled phase 2 trial[J].Lancet Oncol,2015,16(13):1324-1334.
40 Yoon HH,Foster NR,Meyers JP,et al.Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin,paclitaxel,and everolimus:NCCTG N0871(alliance)[J].Ann Oncol,2016,27(2):339-344.
41 National Cancer Institute.Molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01827384?term=NCT01827384&rank=1,2017.
42 Anderson Cancer Center.Randomized study evaluating molecular profiling and targeted agents in metastatic cancer[DB/OL].https://clinicaltrials.gov/ct2/show/NCT0215
2254?term=IMPACT2&rank=4,2017.
43 Gustave Roussy,Cancer Campus,Grand Paris.Trial comparing a strategy based on molecular analysis to the empiric strategy in patients sith CUP[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01540058?term=GEFCAPI04&rank=1,2017.
44 Hannouf MB,Winquist E,Mahmud SM,et al.Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary[J].Pharmacogenomics J,2017,17(3):286-300.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[4]	徐秋菊,张广文. 伏核微量注射异丁司特对吗啡成瘾大鼠甩尾痛阈的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 211-214.
[5]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[6]	秦文,赵楠楠,韩永焕,徐亚君. ZNF436在胃癌中的表达及调控WNT/β-catenin对胃癌细胞迁移及侵袭的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 222-227.
[7]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[8]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[9]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[10]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[11]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[12]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[13]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[14]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[15]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.